Evidence map›Paper›PMID 42055006›Full record

ArticleDevelopmental cell2026

The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion.

Lan Wang, Chris R Harris, Crissy Dudgeon, Orjola Prela, Juliana Cazarin, Ching-Hua Shih, Christina Davidson, Anthony Casabianca, Subhajyoti De, Wade Narrow and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Developmental cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Lan WangDepartment of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Chris R HarrisDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Crissy DudgeonRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Orjola PrelaDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Juliana CazarinDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Ching-Hua ShihDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Christina DavidsonDepartment of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Anthony CasabiancaDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Subhajyoti DeRutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Wade NarrowDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Jennifer BeckerDewitt Daughtry Department of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
Paul M GrandgenettEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Michael A HollingsworthEppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Jean L GremDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Minsoo KimDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Yeonsun HongCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Scott GerberCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Paula M VertinoWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Chongfeng GaoCenter for Advanced Research Technologies, University of Rochester Medical Center, Rochester, NY, USA.
Zachary KlamerCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Anna RepeshCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Yansheng HaoDepartment of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Allison T RyanDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Mitchell BreitenbachDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Anna BianchiDewitt Daughtry Department of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
Jashodeep DattaDewitt Daughtry Department of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.
Brian J AltmanWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Brian HaabCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Darren R CarpizoDepartment of Surgery, Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Electronic address: darren_carpizo@urmc.rochester.edu.

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
University of Rochester Wilmot Cancer Institute Support GrantP30CA272302 · NCI · UNIVERSITY OF ROCHESTER · PI JONATHAN W FRIEDBERG · 2025 to 2026
$6.4M
Relaxed Polymerase Pausing as a Driver of Epigenetic Plasticity and Cancer Cell InvasionR01CA250531 · NCI · UNIVERSITY OF ROCHESTER · PI VERTINO, PAULA M. · 2021 to 2025
$2.2M
Computational genomic analysis of genomic variations in human tissuesR35GM149224 · NIGMS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Subhajyoti De · 2023 to 2026
$1.4M
Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer ResearchR50CA211462 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Paul M Grandgenett · 2016 to 2026
$1.4M
Disruption of the circadian clock in lung cancerR01CA282225 · NCI · UNIVERSITY OF ROCHESTER · PI Brian James Altman · 2024 to 2026
$1.3M
Targeting Intrinsic and Extrinsic Barriers to Treat Metastatic Pancreatic CancerR01CA295861 · NCI · UNIVERSITY OF ROCHESTER · PI Darren Richard Carpizo, Scott Andrew Gerber · 2025 to 2026
$1.3M
NCI NIH HHS P30 CA036727NCI NIH HHS P30 CA272302NCI NIH HHS R01 CA250531NCI NIH HHS R01 CA282225NCI NIH HHS R01 CA295861NCI NIH HHS R50 CA211462NCI NIH HHS U01 CA210240NIGMS NIH HHS R35 GM149224
6 · The paper itself

Abstract

The mechanisms that regulate immune evasion by pancreatic ductal adenocarcinomas (PDACs) remain poorly understood. Using a mouse model of resectable PDAC, we identified an unknown role of the circadian rhythm gene Differentially Expressed in Chondrocytes 2 (Dec2) in regulating tumor progression and dormancy. Deletion of Dec2 from tumor cells substantially increased mouse survival after resection due to an immune-mediated mechanism, as the survival benefit was abrogated under immunodeficient conditions. Dec2 promotes immune evasion by repressing major histocompatibility complex class I (MHC-I)-dependent antigen presentation and by repolarizing the tumor microenvironment from immunologically cold (low T cell infiltration) to hot (elevated T cell infiltration). Dec2 is also a regulator of circadian rhythms, and we found that genes involved in MHC-I antigen presentation and MHC-I surface localization oscillated in a circadian manner, which was lost upon deletion of Dec2 in vitro. We conclude that Dec2 promotes primary PDAC progression and likely metastatic dormancy through immune evasion.

Indexed as

Carcinoma, Pancreatic DuctalCircadian RhythmImmune EvasionPancreatic NeoplasmsTumor EscapeAnimalsAntigen PresentationCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHistocompatibility Antigens Class IHumansMiceMice, Inbred C57BLTumor MicroenvironmentHistocompatibility Antigens Class Iantigen presentationcancer dormancycircadian rhythmDec2immune evasionmouse model resectable PDACpancreatic ductal adenocarcinomasTRA

Identifiers

PMID42055006
PMCPMC13519945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.